Table 2 |
|||||||
|
ED 50s & 90s of Doxovir™ to Adenovirus Type 5. Effective dose (ED) 50s and 90s of Doxovir™ (CTC-96) against Adenovirus type 5 in HeLa (human cervical carcinoma), A549 (human cervical carcinoma) and SIRC (rabbit corneal) cells during Virucidal, Antiviral and Viral Inactivation assays. |
|||||||
|
(MIC 50 (μg/ml) |
(MIC 90 (μg/ml) |
||||||
|
|
|||||||
|
HeLa (human cervical carcinoma) |
Virucidal |
33.0 |
± |
6.9 |
46.6 |
± |
9.7 |
|
Antiviral |
4.5 |
± |
0.1 |
21.8 |
± |
1.2 |
|
|
Viral Inactivation |
16.5 |
± |
2.5 |
43.0 |
± |
1.3 |
|
|
A549 (human lung carcinoma) |
Virucidal |
31.7 |
± |
1.9 |
46.3 |
± |
2.6 |
|
Antiviral |
4.7 |
± |
0.2 |
20.8 |
± |
1.9 |
|
|
Viral Inactivation |
4.2 |
± |
1.1 |
37.5 |
± |
6.5 |
|
|
SIRC (rabbit cornea) |
Virucidal |
13.6 |
± |
2.3 |
22.7 |
± |
3.5 |
|
Antiviral |
27.3 |
± |
8.3 |
45.5 |
± |
1.6 |
|
|
Viral Inactivation |
13.1 |
± |
2.9 |
23.9 |
± |
4.9 |
|
|
|
|||||||
|
Epstein et al. BMC Ophthalmology 2006 6:22 doi:10.1186/1471-2415-6-22 |
|||||||
